4-(4-hexylcarbamoylmethoxy-5-methyl-1,3-thiazol-2-yl)benzoic acid | 920269-62-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-hexylcarbamoylmethoxy-5-methyl-1,3-thiazol-2-yl)benzoic acid
• 英文别名: 4-(4-hexylcarbamoylmethoxy-5-methyl-thiazol-2-yl)-benzoic acid；4-{4-[2-(Hexylamino)-2-oxoethoxy]-5-methyl-1,3-thiazol-2-yl}benzoic acid；4-[4-[2-(hexylamino)-2-oxoethoxy]-5-methyl-1,3-thiazol-2-yl]benzoic acid
• CAS: 920269-62-1
• 化学式: C₁₉H₂₄N₂O₄S
• 分子量: 376.477
• InChiKey: BUVAUYANRKGVEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  在 lithium hydroxide 、 水 、 三氟乙酸 作用下， 反应 72.0h， 生成 4-(4-hexylcarbamoylmethoxy-5-methyl-1,3-thiazol-2-yl)benzoic acid
  参考文献：
  名称：

  WO2007/9083

  摘要：

  公开号：

文献信息

• COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS
  申请人：Olsson Roger

  公开号：US20090176837A1

  公开（公告）日：2009-07-09

  Disclosed herein are novel compounds with activity at RARβ 2 receptors. Further disclosed are the use of such compounds for treatment of or to alleviate symptoms of cancer, neurological disorders such as memory deficits and schizophrenia, neurodegenerative disorders such as Parkinson's and Alzheimer's diseases, inflammatory disorders such as psoriasis and rheumatoid arthritis, eye disorders and depression.

  本文揭示了具有对RARβ 2受体活性的新化合物。进一步揭示了这些化合物的用途，用于治疗或缓解癌症、神经系统疾病（如记忆障碍和精神分裂症）、神经退行性疾病（如帕金森病和阿尔茨海默病）、炎症性疾病（如银屑病和类风湿性关节炎）、眼部疾病和抑郁症状。
• Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
  申请人：Cornell University

  公开号：US11160769B2

  公开（公告）日：2021-11-02

  This invention relates to pharmaceutical compositions and methods for treating (including managing) or preventing metabolic syndrome related conditions using one or more RAR e.g., RAR agonists. Such conditions include, but are not limited to, diseases in pancreas, liver, kidney, testes, muscle, or adipose tissue, as well as other organs that are associated with high fat diet and/or vitamin A deficiency, as well as other conditions associated with abnormal level of triglyceride, cholesterol and/or glucose.

  本发明涉及使用一种或多种 RAR（如 RAR 激动剂）治疗（包括控制）或预防代谢综合征相关疾病的药物组合物和方法。这些病症包括但不限于胰腺、肝脏、肾脏、睾丸、肌肉或脂肪组织以及与高脂肪饮食和/或维生素 A 缺乏有关的其他器官的疾病，以及与甘油三酯、胆固醇和/或葡萄糖水平异常有关的其他病症。
• Compositions and methods for providing cardioprotective effects
  申请人：Cornell University

  公开号：US11191755B2

  公开（公告）日：2021-12-07

  The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention provides compositions and methods for treating cardiovascular ailments, for example, ischemia/reperfusion (I/R) injury, cardiac arrhythmias, oxidative stress, or cardiac failure by administering a retinoic acid receptor-beta (RARβ) agonist.

  本发明提供了为受试者提供心脏保护作用的组合物和方法。具体来说，本发明提供了通过施用视黄酸受体-β（RARβ）激动剂治疗心血管疾病（例如缺血/再灌注（I/R）损伤、心律失常、氧化应激或心力衰竭）的组合物和方法。
• Design, Synthesis, and Structure−Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands
  作者：Birgitte W. Lund、Anne Eeg Knapp、Fabrice Piu、Natalie K. Gauthier、Mikael Begtrup、Uli Hacksell、Roger Olsson

  DOI：10.1021/jm801532e

  日期：2009.3.26

  We recently discovered the isoform selective RAR beta 2 ligand 4'-octyl-4-biphenylcarboxylic acid (3, AC-55649). Although 3 is highly potent at RAR beta 2 and displays excellent selectivity, solubility issues make it unsuitable for drug development. Herein we describe the exploration of the SAR in a biphenyl and a phenylthiazole series of analogues of 3. This ultimately led to the design of 28, a novel, orally available ligand with excellent isoform selectivity for the RAR beta 2.
• COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS
  申请人：CORNELL UNIVERSITY

  公开号：US20220296579A1

  公开（公告）日：2022-09-22

  The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention provides compositions and methods for treating cardiovascular ailments, for example, ischemia/reperfusion (I/R) injury, cardiac arrhythmias, oxidative stress, or cardiac failure by administering a retinoic acid receptor-beta (RARβ) agonist.